Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran

Authors Information
Article Notes and Dates
To Cite : Baniasadi N, Salajegheh F, Pardakhty A, Seyedmirzaee S M, Hayatbakhsh M M, et al. Effects of Pentoxifylline on Non-Alcoholic Steatohepatitis: A Randomized, Double-Blind, Placebo-Controlled Trial in Iran, Hepat Mon. 2015 ;15(11):e58823. doi: 10.5812/hepatmon.33462.
Copyright: Copyright © 2015, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011; 33(5): 525-40[DOI][PubMed]
  • 2. Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci. 2014; 15(5): 8591-638[DOI][PubMed]
  • 3. Choi S, Diehl AM. Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol. 2005; 21(6): 702-7[PubMed]
  • 4. Targher G, Arcaro G. Non-alcoholic fatty liver disease and increased risk of cardiovascular disease. Atherosclerosis. 2007; 191(2): 235-40[DOI][PubMed]
  • 5. Hotamisligil GS, Arner P, Caro JF, Atkinson RL, Spiegelman BM. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995; 95(5): 2409-15[DOI][PubMed]
  • 6. Hotamisligil GS. The role of TNFalpha and TNF receptors in obesity and insulin resistance. J Intern Med. 1999; 245(6): 621-5[PubMed]
  • 7. Muriel P, Fernandez-Martinez E, Perez-Alvarez V, Lara-Ochoa F, Ponce S, Garcia J, et al. Thalidomide ameliorates carbon tetrachloride induced cirrhosis in the rat. Eur J Gastroenterol Hepatol. 2003; 15(9): 951-7[DOI][PubMed]
  • 8. Tilg H, Diehl AM. Cytokines in alcoholic and nonalcoholic steatohepatitis. N Engl J Med. 2000; 343(20): 1467-76[DOI][PubMed]
  • 9. Lindmark E, Diderholm E, Wallentin L, Siegbahn A. Relationship between interleukin 6 and mortality in patients with unstable coronary artery disease: effects of an early invasive or noninvasive strategy. JAMA. 2001; 286(17): 2107-13[PubMed]
  • 10. Marra F, Gastaldelli A, Svegliati Baroni G, Tell G, Tiribelli C. Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis. Trends Mol Med. 2008; 14(2): 72-81[DOI][PubMed]
  • 11. Perseghin G, Petersen K, Shulman GI. Cellular mechanism of insulin resistance: potential links with inflammation. Int J Obes Relat Metab Disord. 2003; 27 Suppl 3-11[DOI][PubMed]
  • 12. Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006; 116(7): 1793-801[DOI][PubMed]
  • 13. Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, et al. Adipokines and cytokines in non-alcoholic fatty liver disease. Aliment Pharmacol Ther. 2008; 27(5): 412-21[DOI][PubMed]
  • 14. Koppe SW, Sahai A, Malladi P, Whitington PF, Green RM. Pentoxifylline attenuates steatohepatitis induced by the methionine choline deficient diet. J Hepatol. 2004; 41(4): 592-8[DOI][PubMed]
  • 15. Hernandez E, Correa A, Bucio L, Souza V, Kershenobich D, Gutierrez-Ruiz MC. Pentoxifylline diminished acetaldehyde-induced collagen production in hepatic stellate cells by decreasing interleukin-6 expression. Pharmacol Res. 2002; 46(5): 435-43[PubMed]
  • 16. Balibrea JL, Arias-Diaz J, Garcia C, Vara E. Effect of pentoxifylline and somatostatin on tumour necrosis factor production by human pulmonary macrophages. Circ Shock. 1994; 43(2): 51-6[PubMed]
  • 17. Lee YM, Sutedja DS, Wai CT, Dan YY, Aung MO, Zhou L, et al. A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int. 2008; 2(2): 196-201[DOI][PubMed]
  • 18. Tuncer İ, Uygan İ, Dülger H, Türkdoğan K, Şekeroğlu MR, Kösem M. The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1β, Il-6, Il-8 and TNF-α levels in nonalcoholic fatty liver. Eastyern J Med. 2003; 8: 27-32
  • 19. Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007; 16(1): 39-46[PubMed]
  • 20. Adams LA, Zein CO, Angulo P, Lindor KD. A pilot trial of pentoxifylline in nonalcoholic steatohepatitis. Am J Gastroenterol. 2004; 99(12): 2365-8[DOI][PubMed]
  • 21. Satapathy SK, Sakhuja P, Malhotra V, Sharma BC, Sarin SK. Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol. 2007; 22(5): 634-8[DOI][PubMed]
  • 22. Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Seminars in diagnostic pathology. : 330-8
  • 23. Yeh MM, Brunt EM. Pathology of nonalcoholic fatty liver disease. Am J Clin Pathol. 2007; 128(5): 837-47[DOI][PubMed]
  • 24. Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000; 119(6): 1637-48[PubMed]
  • 25. Van Wagner LB, Koppe SW, Brunt EM, Gottstein J, Gardikiotes K, Green RM, et al. Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial. Ann Hepatol. 2011; 10(3): 277-86[PubMed]
  • 26. Buranawui W, Thung-u-thaisri P, Pramoolsinsap C. Pentoxifylline for treatment of non-alcoholic fatty liver disease (NAFLD): a randomized, placebo-controlled study [Abstract s2161]. Gastroenterology A. 2006; 330
  • 27. Zein CO, Yerian LM, Gogate P, Lopez R, Kirwan JP, Feldstein AE, et al. Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial. Hepatology. 2011; 54(5): 1610-9[DOI][PubMed]
  • 28. Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011; 10: 49[DOI][PubMed]
  • 29. Du J, Ma YY, Yu CH, Li YM. Effects of pentoxifylline on nonalcoholic fatty liver disease: a meta-analysis. World J Gastroenterol. 2014; 20(2): 569-77[DOI][PubMed]
  • 30. Jamali R, Dowlatshahi S, Hajatian M. The effect of Pentoxifylline on Liver function tests in Non-alcoholic Fatty Liver Disease Non-diabetic Patients. Govaresh. 2015; 20(2): 90-6
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check